[DOI] [PubMed] [Google Scholar] 56.Mann J.F., Fonseca V., Mosenzon O., Raz I., Goldman B., Idorn T., von Scholten B.J., Poulter N.R., LEADER Publication Committee on behalf of the LEADER Trial Investigators Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 di-abetes mellitus and chronic kidney disease: Results from the LEADER trial
If appropriate, tirzepatide is prescribed with structured dosing instructions
We next examined whether CNS GLP-1R is also essential for the full weight loss effects of mGIPR-Ab/P1 treatment
Patients should check with multiple pharmacies, consult providers about alternative dosing options , or explore FDA-approved weight management programs
What About "Ozempic Breath"